News
Rna Diagnostics Completes Patient Recruitment in BREVITY Clinical Trial for Early Breast Cancer
Toronto, Ont., Canada, May 27, 2026 — Rna Diagnostics Inc., a clinical-stage molecular diagnostics company, today announced that patient recruitment has been completed for BREVITY, the Company-sponsored prospective clinical trial evaluating the RNA Disruption Assay™...
Ontario Government Invests $1,157,000 in Rna Diagnostics to Launch Veridapt DX™ Test Services
Toronto, Ont., Canada, Feb. 5, 2026 — The Ontario government is investing $1,157,000 in Rna Diagnostics – a clinical-stage molecular diagnostics company – through the Northern Ontario Heritage Fund Corporation (NOHFC). The funding will help Rna Diagnostics advance...
New research supports value of the RNA disruption assay to predict chemotherapy outcomes for early-stage breast cancer
Toronto, Ont., Canada, Dec. 8, 2025 — A new study by scientists at the Institute of Cancer Research (Oslo University Hospital) and Rna Diagnostics, a clinical-stage molecular diagnostics company, supports the use of the RNA disruption assay (RDA) to predict tumour...
Dr. Terry Mamounas, MD, MPH, FACS, joins Rna Diagnostics’ Clinical Advisory Board
Dr. Terry Mamounas, MD, MPH, FACS Toronto, Ont., Canada, Feb. 6, 2025 – Rna Diagnostics, an innovative developer of a predictive biomarker technology for early-stage cancer care, is pleased to announce that Dr. Terry Mamounas, MD, MPH, FACS, one of the world’s...
Rna Diagnostics Inc. announces the successful completion of phase 1 of BREVITY, a large-scale international trial of the RNA Disruption Assay in breast cancer
Toronto, Ont., - Rna Diagnostics, a Canadian cancer diagnostics company, is pleased to announce the results from phase 1 of the BREVITY (Breast Cancer Response Evaluation for Individualized Therapy) clinical trial – that aims to validate the utility of the RNA...
Stefan Glück, MD, PhD, FRCPC appointed Chief Medical Officer of Rna Diagnostics
John Connolly, President and Chief Executive Officer of Rna Diagnostics is pleased to announce the appointment of Dr. Stefan Glück, MD, PhD, FRCCP to the position of Chief Medical Officer. Dr. Glück has had a distinguished career in breast cancer treatment...